Toxic Exposures Translational Research Award
ID: 355158Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355158
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TERP TRA) to support impactful translational research focused on military-related toxic exposures. This grant aims to accelerate the movement of promising ideas into clinical applications, including health care products and interventions, while addressing the health outcomes and mitigation strategies associated with toxic exposures faced by Service Members, Veterans, and their families. With an estimated total program funding of $12.8 million and an expected six awards, the application process includes a pre-application deadline of August 13, 2024, and a full application deadline of November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524TERPTRA-GG.pdf
    The Department of Defense (DOD) has announced the FY24 Toxic Exposures Translational Research Award aimed at advancing research related to military-related toxic exposures. This funding opportunity, part of the Defense Health Program, is seeking impactful translational research that identifies causes, health outcomes, and mitigation strategies associated with toxic exposures faced by Service Members, Veterans, and their families. The program has specific submission deadlines, including a pre-application by August 13, 2024, and a full application by November 7, 2024, with a total funding of $30 million available. Key research goals include elucidating mechanisms of adverse health effects, developing diagnostics and therapies, and enhancing prevention strategies. Eligible applicants encompass a range of organizations, including academic institutions and non-profits, with emphasis on collaboration with DOD and VA researchers. Applications should demonstrate an understanding of how proposed research will translate into clinical applications, benefiting both military and civilian populations while adhering to the defined exclusionary criteria regarding classified research and clinical trials. The review process highlights rigorous criteria for assessing proposals to ensure the advancement of relevant medical research initiatives.
    Similar Opportunities
    Toxic Exposures Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Toxic Exposures Investigator-Initiated Research Award (TERP IIRA) to support research addressing health outcomes related to military-related toxic exposures. This grant aims to fund studies that contribute significantly to understanding and improving patient care for diseases associated with such exposures, encompassing all research phases from basic laboratory studies to translational research involving human subjects and animal models. With an estimated total program funding of $3.2 million and the expectation of awarding four grants, interested applicants must submit pre-applications by August 13, 2024, and full applications by November 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD VRP, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Translational Research Award (VRP TRA) to support innovative translational research aimed at advancing the prevention, diagnosis, and treatment of eye injuries and visual dysfunction associated with military service. This grant opportunity encourages projects that establish a clear path for transforming promising discoveries into clinical applications, including new drugs and devices, with a focus on collaboration with regulatory experts to facilitate the approval process. With an estimated total program funding of $1.6 million and the expectation of one award, interested applicants must submit a pre-application by July 11, 2024, followed by a full application by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    DoD VRP, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the FY24 Vision Clinical Trial Award to fund innovative clinical trials aimed at addressing eye injuries and visual dysfunctions related to military service. This grant opportunity supports early-phase clinical trials that evaluate new products, pharmacologic agents, and devices, with a focus on improving treatment outcomes for service-connected visual impairments. With an estimated total program funding of $2.56 million and an anticipated award amount of up to $1.6 million per application, interested applicants must submit their pre-applications by July 11, 2024, and full applications by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Focused Translational Team Science Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Focused Translational Team Science Award (FTTSA) under the Vision Research Program (VRP) to advance research on eye injuries and visual dysfunction resulting from military exposure. This grant aims to foster collaborative research initiatives that address significant gaps in understanding, prevention, and treatment of eye trauma, with applications required to include three to five synergistic research projects that align with the program's focus areas. With an estimated total program funding of $6.4 million and a maximum budget of $4 million per project, the opportunity is open to unrestricted applicants, and full applications are due by November 8, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD VRP, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Vision Research Program (VRP) Investigator-Initiated Research Award, aimed at advancing research on eye injuries related to military service. This grant opportunity seeks innovative proposals that address the understanding, prevention, diagnosis, and treatment of eye injuries associated with military exposure, with two funding levels available to accommodate projects at different stages of maturity. The program emphasizes the importance of improving care for service members and veterans affected by visual injuries, with an estimated total funding of $832,000 and the expectation of awarding approximately seven grants. Interested applicants must submit a pre-application by July 11, 2024, followed by a full application due by November 8, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.